May 8, 2020

Alverno Laboratories presents two significant updates: the addition of qualitative COVID-19 IgG antibody testing conducted by ARUP Laboratories and an update to its pain management panel, now comprising 78 different drugs and metabolites. The COVID-19 IgG antibody test can detect antibodies typically present around two weeks post-symptom onset, aiding in indicating exposure to SARS-CoV2; however, it does not establish definitive immunity. Alverno now performs Fentanyl and Buprenorphine screenings in-house, with reflex quantitation if positive, offering faster turnaround times. The pain management panel, effective since May 5, 2020, requires a urine sample and includes a comprehensive list of drugs and metabolites, with results available within a day after sample receipt. More information on specimen requirements and testing availability can be found on Alverno's website or by contacting Client Services.